KTRA Kintara Therapeutics, Inc.

Located in San Diego, California, Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs. Kintara is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC.

$0.57
As of 12/03/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  02/22/2013
Outstanding shares:  48,535,338
Average volume:  1,096,413
Market cap:   $30,577,263
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    49720K101
ISIN:        US49720K1016
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   4.52
PS ratio:   0.00
Return on equity:   -129.13%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy